PYPD - PolyPid Ltd. Stock Price and Quote

PYPD [NASD]

Index	-	P/E	-	EPS (ttm)	-2.04	Insider Own	21.26%	Shs Outstand	19.66M	Perf Week	-8.81%
Market Cap	10.58M	Forward P/E	-	EPS next Y	-0.75	Insider Trans	0.00%	Shs Float	15.48M	Perf Month	-28.79%
Income	-39.50M	PEG	-	EPS next Q	-0.28	Inst Own	12.80%	Short Float / Ratio	1.20% / 0.47	Perf Quarter	-30.67%
Sales	-	P/S	-	EPS this Y	10.60%	Inst Trans	-18.69%	Short Interest	0.19M	Perf Half Y	-59.39%
Book/sh	0.30	P/B	1.78	EPS next Y	-11.60%	ROA	-125.80%	Target Price	3.38	Perf Year	-90.70%
Cash/sh	0.64	P/C	0.84	EPS next 5Y	-	ROE	-242.00%	52W Range	0.50 - 6.90	Perf YTD	-25.48%
Dividend	-	P/FCF	-	EPS past 5Y	10.10%	ROI	-	52W High	-92.47%	Beta	-
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	-	Gross Margin	-	52W Low	3.53%	ATR	0.06
Employees	75	Current Ratio	1.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	28.36	Volatility	8.32% 8.98%
Optionable	Yes	Debt/Eq	1.97	EPS Q/Q	53.80%	Profit Margin	-	Rel Volume	0.16	Prev Close	0.53
Shortable	Yes	LT Debt/Eq	1.29	Earnings	Feb 08 BMO	Payout	-	Avg Volume	397.74K	Price	0.52
Recom	2.20	SMA20	-17.94%	SMA50	-31.07%	SMA200	-77.09%	Volume	16,602	Change	-2.66%

Sep-14-21

Initiated

JMP Securities

Mkt Outperform

$14

Jul-30-21

Initiated

Cantor Fitzgerald

Overweight

$24

Nov-24-20

Upgrade

Raymond James

Outperform → Strong Buy

Aug-10-20

Initiated

Alliance Global Partners

Buy

$27

Jul-21-20

Initiated

Raymond James

Outperform

$23

Jul-21-20

Initiated

BMO Capital Markets

Outperform

$30

Jul-21-20

Initiated

Barclays

Overweight

$22

Mar-07-23 08:00AM	PolyPid to Present at the Barclays Global Healthcare Conference GlobeNewswire +5.34%
Feb-09-23 03:22PM	PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript Insider Monkey
Feb-08-23 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results GlobeNewswire -12.81%
Jan-31-23 07:00AM	PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023 GlobeNewswire
Jan-24-23 07:00AM	PolyPid Provides Positive Regulatory Update for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery GlobeNewswire +10.20%
07:00AM	Loading…
Jan-03-23 07:00AM	PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery GlobeNewswire +6.95%
Dec-12-22 07:00AM	PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery GlobeNewswire
Dec-09-22 04:01PM	PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification GlobeNewswire -6.16%
Nov-29-22 07:00AM	PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association GlobeNewswire
Nov-09-22 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results GlobeNewswire -9.59%
Oct-26-22 07:00AM	PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022 GlobeNewswire
Oct-20-22 07:09AM	PolyPid Announces Cost Reduction Plan GlobeNewswire
Sep-28-22 08:57AM	PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery GlobeNewswire
Sep-19-22 07:00AM	PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery GlobeNewswire
Sep-12-22 07:00AM	PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the European Society for Coloproctology Scientific Conference GlobeNewswire +58.33%
03:25PM	Loading…
Sep-06-22 03:25PM	This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout Benzinga -19.58%
Sep-02-22 10:04AM	PolyPid's Lead Program Flunks Abdominal Surgery Study, Shares Tank Benzinga -73.47%
08:37AM	PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery GlobeNewswire
Aug-31-22 09:55AM	Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet Zacks -5.64%
09:40AM	Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year? Zacks
Aug-30-22 07:00AM	PolyPid Announces Presentation at the 2022 Military Health System Research Symposium GlobeNewswire
Aug-15-22 12:00PM	All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy Zacks +5.13%
09:55AM	Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade Zacks
Aug-10-22 07:00AM	PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results GlobeNewswire
Aug-03-22 07:00AM	PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX in Europe GlobeNewswire +7.83%
Jul-27-22 07:00AM	PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022 GlobeNewswire +5.97%
Jul-25-22 07:00AM	PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the Midwest Surgical Association 2022 Annual Meeting GlobeNewswire +8.09%
Jul-05-22 07:00AM	PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO GlobeNewswire -5.29%
Jun-15-22 07:00AM	PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections GlobeNewswire +7.59%
Jun-06-22 07:00AM	PolyPid Announces Presentation of D-PLEX Phase 2 Clinical Data at ASM Microbe 2022 GlobeNewswire
07:00AM	Loading…
Jun-02-22 07:00AM	PolyPid to Present at the JMP Securities 2022 Life Sciences Conference GlobeNewswire
Jun-01-22 07:00AM	PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects GlobeNewswire
May-31-22 07:00AM	PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery GlobeNewswire +7.60%
May-23-22 12:04PM	Why PolyPid Shares Are Gaining Today Benzinga
07:00AM	PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis GlobeNewswire
May-16-22 09:55AM	Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 289%: Read This Before Placing a Bet Zacks -8.60%
May-11-22 07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results GlobeNewswire
Apr-27-22 07:00AM	PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022 GlobeNewswire
Apr-25-22 07:30AM	PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine GlobeNewswire
Apr-12-22 08:00AM	PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting GlobeNewswire
Apr-06-22 07:00AM	PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility GlobeNewswire
Mar-28-22 02:11PM	We Think PolyPid (NASDAQ:PYPD) Needs To Drive Business Growth Carefully Simply Wall St.
Mar-08-22 07:00AM	PolyPid to Deliver Poster Presentation at SAGES 2022 GlobeNewswire
Mar-02-22 07:00AM	PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX in Abdominal Surgery GlobeNewswire +13.33%
Mar-01-22 07:00AM	PolyPid to Present at the Barclays Global Healthcare Conference GlobeNewswire +11.39%
Feb-09-22 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results GlobeNewswire +5.16%
Jan-26-22 07:30AM	PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022 GlobeNewswire -5.46%
Jan-04-22 07:30AM	PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board GlobeNewswire
Jan-03-22 07:30AM	PolyPid Announces Planned CEO Transition GlobeNewswire +6.27%
Dec-27-21 09:22AM	How Much Of PolyPid Ltd. (NASDAQ:PYPD) Do Insiders Own? Simply Wall St.
Dec-14-21 03:26PM	10 Micro-Cap Stocks to Buy According to Cathie Wood Insider Monkey
Nov-18-21 07:00AM	PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX in Abdominal Surgery GlobeNewswire
Nov-16-21 10:20AM	Does PolyPid Ltd. (PYPD) Have the Potential to Rally 166% as Wall Street Analysts Expect? Zacks
07:00AM	PolyPid Appoints New Oncology Advisory Board Member GlobeNewswire
Nov-10-21 07:00AM	PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire -7.50%
Nov-01-21 07:00AM	PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021 GlobeNewswire
Sep-27-21 02:08PM	We're Keeping An Eye On PolyPid's (NASDAQ:PYPD) Cash Burn Rate Simply Wall St.
Sep-20-21 07:00AM	PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-13-21 11:00AM	PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor Benzinga -7.81%
07:30AM	PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer GlobeNewswire
Aug-17-21 08:00AM	PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress GlobeNewswire
Aug-11-21 07:00AM	PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-21 08:00AM	PolyPid to Present at the Investor Summit Virtual Conference on August 18, 2021 GlobeNewswire +12.86%
Jul-28-21 07:00AM	PolyPid to Report Second Quarter 2021 Financial Results and Operational Highlights on August 11, 2021 GlobeNewswire
Jul-12-21 08:00AM	PolyPid Strengthens Executive Team, Appointing Dr. Anthony Senagore as Senior Medical Director GlobeNewswire
Jun-28-21 09:30AM	What Kind Of Shareholders Hold The Majority In PolyPid Ltd.'s (NASDAQ:PYPD) Shares? Simply Wall St.
Jun-23-21 06:30AM	PolyPid Presents today at The Raymond James Human Health Innovation Conference GlobeNewswire
Jun-22-21 09:58PM	Is PolyPid Ltd. (PYPD) A Good Stock To Buy? Insider Monkey
Jun-02-21 09:10AM	PolyPid to Present at Upcoming Healthcare Investor Conferences GlobeNewswire
May-19-21 12:51PM	PolyPid's Single Pivotal Study Sufficient To Support Potential Approval Of D-PLEX100 For Infections After Colorectal Surgery Benzinga
08:00AM	PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX Development Program GlobeNewswire
May-12-21 07:00AM	PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
06:45AM	Polypid Ltd to Host Earnings Call ACCESSWIRE
Apr-29-21 07:00AM	PolyPid to Report First Quarter 2021 Financial Results and Operational Highlights on May 12, 2021 GlobeNewswire
Mar-29-21 08:33AM	Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation Simply Wall St.
Feb-23-21 07:30AM	PolyPid to Participate in Upcoming Investor Conferences GlobeNewswire -10.87%
Feb-16-21 07:31AM	PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX for the Prevention of Post-Abdominal Surgery Incisional Infections GlobeNewswire
Feb-10-21 07:34AM	The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga +7.76%
07:00AM	PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire
06:30AM	Polypid Ltd to Host Earnings Call ACCESSWIRE
Jan-27-21 07:30AM	PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021 GlobeNewswire
Dec-22-20 07:00AM	PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program GlobeNewswire
Dec-16-20 07:00AM	PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX for the Prevention of Post-Abdominal Surgery Incisional Infections GlobeNewswire -5.13%
Dec-03-20 08:00AM	PolyPid to Host Key Opinion Leader Call Discussing D-PLEX and the Prevention of Surgical Site Infections GlobeNewswire -5.32%
Nov-24-20 08:17AM	PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX for the Prevention of Surgical Site Infections in Colorectal Surgery GlobeNewswire +15.54%
Nov-11-20 06:30AM	PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-04-20 08:45AM	PolyPid to Participate in Three Upcoming Investor Conferences GlobeNewswire
Oct-28-20 07:00AM	PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020 GlobeNewswire -7.09%
Oct-14-20 10:29AM	Raymond James Says These 3 Stocks Could Surge Over 100% From Current Levels TipRanks
Sep-28-20 01:28PM	We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth Simply Wall St. -12.87%
Aug-19-20 07:00AM	PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-05-20 04:01PM	PolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020 GlobeNewswire
Aug-03-20 07:00AM	PolyPid Granted Fast Track Designation from FDA for D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery GlobeNewswire
Jul-27-20 07:00AM	PolyPid to Present Phase 2 Results of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions GlobeNewswire
Jul-01-20 09:00AM	PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections PR Newswire -8.04%
Jun-30-20 04:01PM	PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire -5.06%
Jun-26-20 02:04AM	PolyPid Ltd. Announces Pricing of Initial Public Offering PR Newswire

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience